190 results on '"Martinez, Fernando J."'
Search Results
2. Comparison of Pirfenidone and Nintedanib: Post-Hoc Analysis of the CleanUP-IPF Study
3. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
4. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort
5. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
6. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study
7. Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts
8. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study
9. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis
10. Assessing mortality differences across acute respiratory failure management strategies in Covid-19
11. Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review
12. Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR
13. Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study
14. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD
15. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD
16. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
17. Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease
18. Perplexing mortality data from triple therapy trials in COPD – Author's reply
19. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases
20. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
21. Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
22. Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction
23. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD
24. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment
25. Clinical Phenotypes of Atopy and Asthma in COPD
26. Serum IgG Levels and Risk of COPD Hospitalization
27. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
28. Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease
29. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life
30. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
31. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
32. A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease
33. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD
34. POINT: Can Screening for COPD Improve Outcomes? Yes
35. Rebuttal From Drs Yawn and Martinez
36. Objectively Measured Chronic Lung Injury on Chest CT
37. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
38. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
39. Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC
40. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
41. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
42. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study
43. Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS
44. Hypersensitivity Pneumonitis
45. Aspirin Use and Respiratory Morbidity in COPD
46. Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers
47. An admixture mapping meta-analysis implicates genetic variation at 18q21 with asthma susceptibility in Latinos
48. Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers
49. Clinical Approach to the Therapy of Asthma-COPD Overlap
50. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.